Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Extracellular vesicles derived from astrocyte-treated with haFGF 14-154 attenuate Alzheimer phenotype in AD mice

Peng D., Wang Y., Xiao Y., Peng M., Mai W., Hu B.

Prospective Study on Neuroinflammation, Chronic Inflammation, published in Theranostics (2022) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Theranostics (2022)
Reported sample size
—
Source database
Europe PMC
PMID
35664060
PMCID
PMC9131260
DOI
10.7150/thno.70951
Citations
44

Abstract (original English)

Background: aFGF content in serum and cerebrospinal fluid is increased in Alzheimer's disease (AD) patients and attenuates the activation of astrocytes. Extracellular vesicles (EVs) are a major mediator in astrocyte-neuron communications. Since excessive or persistent reactive astrocytes lead to chronic inflammation and neuronal dysfunction, and the activation of astrocytes can be inhibited by aFGF, we proposed that the cargoes of astrocyte-derived EVs (AEVs) might be modified by aFGF stimulation, playing an important role in AD progression. However, the mechanisms underlying the role of aFGF remain unclear. Methods: AEVs were isolated from damaged astrocytes, treated with or without aFGF in Aβ-loading condition, and were intranasally administered to AD mice. We determined the ability of AEVs to enter the brain, ameliorate cognitive behavior deficits, alleviate the Aβ burden in the brain, and improve synapse ultrastructure. Subsequently, the miRNAs enriched in AEVs were sequenced to identify the key molecules specifically modified by aFGF. Finally, we explored the protective effects of miR-206-3p inhibition on cognitive deficiency and its regulatory mechanism and determined its role as a specific biomarker for potential AD diagnosis. Results: AEVs stimulated by aFGF (defined as AEVs- Aβ+H ) had favorable neuroprotection in AD pathology by enhancing neurite growth and reduction

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AstrocytesAnimalsMice, TransgenicHumansMiceAlzheimer DiseaseBrain-Derived Neurotrophic FactorMicroRNAsPhenotypeAmyloid beta-Peptides

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research